Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2013

01.01.2013 | Epidemiology

Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis

verfasst von: Mariaelena Pierobon, Cara L. Frankenfeld

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Triple-negative breast cancer (TNBC) is a subtype of breast tumor with unique characteristics in terms of clinical−pathological presentation, prognosis, and response to therapy. Epidemiological investigations focusing on the identification of risk factors involved in the onset and progression of TNBCs have identified unique demographic, anthropometric, and reproductive characteristics involved in the etiopathogenesis of this subtype of breast tumors. This systematic review and meta-analysis evaluates the association between TNBCs and obesity and menopause status. Eligible articles were identified through three databases and secondary reference analysis. The search was conducted from the first record to February 2012. Eleven original articles meeting a priori established inclusion criteria were incorporated in the quantitative analysis. Case−case and case–control comparisons were performed. In addition, a case–case comparison was conducted before and after stratification according to menopausal status. Based on the level of between-study heterogeneity, pooled odds ratio (OR) and 95 % confidence interval were calculated using fixed or random models. The case−case comparison showed a significant association between TNBC and obesity (OR: 1.20; 95 % CI: 1.03−1.40). These results were confirmed by the case–control comparison (OR: 1.24; 95 % CI: 1.06−1.46). Once stratification based on menopausal status was applied to the case–case analysis, significant results were observed only in the pre-menopausal group (OR: 1.43; 95 % CI: 1.23−1.65). According to this analysis, obese women are at a greater risk of presenting with a TNBC than non-obese women, and menopause status may be a mitigating factor. If validated, these findings should be taken into consideration for the development of targeted preventive programs.
Literatur
1.
Zurück zum Zitat Rakha EA, Ellis IO (2009) Triple-negative/basal-like breast cancer: review. Patholology 41(1):40–47CrossRef Rakha EA, Ellis IO (2009) Triple-negative/basal-like breast cancer: review. Patholology 41(1):40–47CrossRef
2.
Zurück zum Zitat Elias AD (2010) Triple-negative breast cancer: a short review. Am J Clin Oncol 33(6):637–645PubMedCrossRef Elias AD (2010) Triple-negative breast cancer: a short review. Am J Clin Oncol 33(6):637–645PubMedCrossRef
3.
Zurück zum Zitat Perou C, Jeffrey S, Van de Rijn M et al (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci 96:9212–9217PubMedCrossRef Perou C, Jeffrey S, Van de Rijn M et al (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci 96:9212–9217PubMedCrossRef
4.
Zurück zum Zitat Perou C, Sorlie T, Eisen M et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef Perou C, Sorlie T, Eisen M et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef
5.
Zurück zum Zitat Sorlie T, Perou C, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 98:10869–10874PubMedCrossRef Sorlie T, Perou C, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 98:10869–10874PubMedCrossRef
6.
Zurück zum Zitat Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948PubMedCrossRef Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948PubMedCrossRef
7.
Zurück zum Zitat Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429–4434PubMedCrossRef Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429–4434PubMedCrossRef
8.
Zurück zum Zitat De Ruijter TC, Veeck J, De Hoon JP et al (2011) Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 137(2):183–192PubMedCrossRef De Ruijter TC, Veeck J, De Hoon JP et al (2011) Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 137(2):183–192PubMedCrossRef
9.
Zurück zum Zitat Irvin WJ Jr, Carey LA (2008) What is triple-negative breast cancer? Eur J Cancer 44(18):2799–2805PubMedCrossRef Irvin WJ Jr, Carey LA (2008) What is triple-negative breast cancer? Eur J Cancer 44(18):2799–2805PubMedCrossRef
10.
Zurück zum Zitat Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer 109(9):1721–1728PubMedCrossRef Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer 109(9):1721–1728PubMedCrossRef
11.
Zurück zum Zitat Vona-Davis L, Rose DP (2009) The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt) 18(6):883–893CrossRef Vona-Davis L, Rose DP (2009) The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt) 18(6):883–893CrossRef
12.
Zurück zum Zitat Dawood S (2010) Triple-negative breast cancer: epidemiology and management options. Drugs 70(17):2247–2258PubMedCrossRef Dawood S (2010) Triple-negative breast cancer: epidemiology and management options. Drugs 70(17):2247–2258PubMedCrossRef
13.
Zurück zum Zitat Rose DP, Vona-Davis L (2010) Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 66(1):33–38PubMedCrossRef Rose DP, Vona-Davis L (2010) Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 66(1):33–38PubMedCrossRef
14.
Zurück zum Zitat Van den Brandt PA, Spiegelman D, Yaun SS et al (2000) Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152(6):514–527PubMedCrossRef Van den Brandt PA, Spiegelman D, Yaun SS et al (2000) Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152(6):514–527PubMedCrossRef
15.
Zurück zum Zitat Lahmann PH, Hoffmann K, Allen N et al (2004) Body size and breast cancer risk: findings from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 111(5):762–771PubMedCrossRef Lahmann PH, Hoffmann K, Allen N et al (2004) Body size and breast cancer risk: findings from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 111(5):762–771PubMedCrossRef
16.
Zurück zum Zitat Rose DP, Vona-Davis L (2009) Influence of obesity on breast cancer receptor status and prognosis. Expert Rev Anticancer Ther 9(8):1091–1101PubMedCrossRef Rose DP, Vona-Davis L (2009) Influence of obesity on breast cancer receptor status and prognosis. Expert Rev Anticancer Ther 9(8):1091–1101PubMedCrossRef
17.
Zurück zum Zitat Phipps AI, Malone KE, Porter PL et al (2008) Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17(8):2078–2086PubMedCrossRef Phipps AI, Malone KE, Porter PL et al (2008) Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17(8):2078–2086PubMedCrossRef
18.
Zurück zum Zitat Aronne LJ (2002) Classification of obesity and assessment of obesity-related health risks. Obes Res 10(Suppl 2):105S–115SPubMedCrossRef Aronne LJ (2002) Classification of obesity and assessment of obesity-related health risks. Obes Res 10(Suppl 2):105S–115SPubMedCrossRef
19.
Zurück zum Zitat Guyatt GH, Oxman AD, Vist G et al (2011) GRADE guidelines: 4. rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol 64(4):407–415PubMedCrossRef Guyatt GH, Oxman AD, Vist G et al (2011) GRADE guidelines: 4. rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol 64(4):407–415PubMedCrossRef
20.
Zurück zum Zitat Sutton AJ, Abrams KR, Jones DR et al (2000) Methods for meta-analysis in medical research. Wiley series in probability and statistics-applied probability and statistics section. Wiley, Hoboken Sutton AJ, Abrams KR, Jones DR et al (2000) Methods for meta-analysis in medical research. Wiley series in probability and statistics-applied probability and statistics section. Wiley, Hoboken
21.
Zurück zum Zitat Millikan RC, Newman B, Tse CK et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123–139PubMedCrossRef Millikan RC, Newman B, Tse CK et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123–139PubMedCrossRef
22.
Zurück zum Zitat Kwan ML, Kushi LH, Weltzien E et al (2009) Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11(3):R31PubMedCrossRef Kwan ML, Kushi LH, Weltzien E et al (2009) Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11(3):R31PubMedCrossRef
23.
Zurück zum Zitat Trivers KF, Lund MJ, Porter PL et al (2009) The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 20(7):1071–1082PubMedCrossRef Trivers KF, Lund MJ, Porter PL et al (2009) The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 20(7):1071–1082PubMedCrossRef
24.
Zurück zum Zitat Gaudet MM, Press MF, Haile RW et al (2011) Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat 130(2):587–597PubMedCrossRef Gaudet MM, Press MF, Haile RW et al (2011) Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat 130(2):587–597PubMedCrossRef
25.
Zurück zum Zitat Phipps AI, Chlebowski RT, Prentice R et al (2011) Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev 20(3):454–463PubMedCrossRef Phipps AI, Chlebowski RT, Prentice R et al (2011) Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev 20(3):454–463PubMedCrossRef
26.
Zurück zum Zitat Suzuki R, Orsini N, Saji S et al (2009) Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status: a meta-analysis. Int J Cancer 124(3):698–712PubMedCrossRef Suzuki R, Orsini N, Saji S et al (2009) Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status: a meta-analysis. Int J Cancer 124(3):698–712PubMedCrossRef
27.
Zurück zum Zitat Vona-Davis L, Rose DP (2007) Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 14(2):189–206PubMedCrossRef Vona-Davis L, Rose DP (2007) Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 14(2):189–206PubMedCrossRef
28.
Zurück zum Zitat Schäffler A, Schölmerich J, Buechler C (2007) Mechanisms of disease: adipokines and breast cancer-endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab 3(4):345–354PubMedCrossRef Schäffler A, Schölmerich J, Buechler C (2007) Mechanisms of disease: adipokines and breast cancer-endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab 3(4):345–354PubMedCrossRef
29.
Zurück zum Zitat Bulun SE, Chen D, Moy I et al (2012) Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab 23(2):83–89PubMedCrossRef Bulun SE, Chen D, Moy I et al (2012) Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab 23(2):83–89PubMedCrossRef
30.
31.
Zurück zum Zitat Lorincz AM, Sukumar S (2006) Molecular links between obesity and breast cancer. Endocr Relat Cancer 13(2):279–292PubMedCrossRef Lorincz AM, Sukumar S (2006) Molecular links between obesity and breast cancer. Endocr Relat Cancer 13(2):279–292PubMedCrossRef
32.
Zurück zum Zitat Federico A, Morgillo F, Tuccillo C et al (2007) Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 121(11):2381–2386PubMedCrossRef Federico A, Morgillo F, Tuccillo C et al (2007) Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 121(11):2381–2386PubMedCrossRef
33.
Zurück zum Zitat Daling JR, Malone KE, Doody DR et al (2001) Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer 92(4):720–729PubMedCrossRef Daling JR, Malone KE, Doody DR et al (2001) Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer 92(4):720–729PubMedCrossRef
34.
Zurück zum Zitat Goodwin PJ, Boyd NF (1990) Body size and breast cancer prognosis: a critical review of the evidence. Breast Cancer Res Treat 16(3):205–214PubMedCrossRef Goodwin PJ, Boyd NF (1990) Body size and breast cancer prognosis: a critical review of the evidence. Breast Cancer Res Treat 16(3):205–214PubMedCrossRef
35.
Zurück zum Zitat Loi S, Milne RL, Friedlander ML et al (2005) Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 14(7):1686–1691PubMedCrossRef Loi S, Milne RL, Friedlander ML et al (2005) Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 14(7):1686–1691PubMedCrossRef
36.
Zurück zum Zitat Gillespie EF, Sorbero ME, Hanauer DA et al (2010) Obesity and angiolymphatic invasion in primary breast cancer. Ann Surg Oncol 17(3):752–759PubMedCrossRef Gillespie EF, Sorbero ME, Hanauer DA et al (2010) Obesity and angiolymphatic invasion in primary breast cancer. Ann Surg Oncol 17(3):752–759PubMedCrossRef
37.
Zurück zum Zitat Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008–2012PubMedCrossRef Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008–2012PubMedCrossRef
38.
Zurück zum Zitat Vona-Davis L, Rose DP, Hazard H et al (2008) Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev 17(12):3319–3324PubMedCrossRef Vona-Davis L, Rose DP, Hazard H et al (2008) Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev 17(12):3319–3324PubMedCrossRef
39.
Zurück zum Zitat Dolle JM, Daling JR, White E et al (2009) Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 18(4):1157–1166PubMedCrossRef Dolle JM, Daling JR, White E et al (2009) Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 18(4):1157–1166PubMedCrossRef
40.
Zurück zum Zitat Stead LA, Lash TL, Sobieraj JE et al (2009) Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 11(2):R18PubMedCrossRef Stead LA, Lash TL, Sobieraj JE et al (2009) Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 11(2):R18PubMedCrossRef
41.
Zurück zum Zitat Yang XR, Chang-Claude J, Goode EL et al (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. Natl Cancer Inst 103(3):250–263CrossRef Yang XR, Chang-Claude J, Goode EL et al (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. Natl Cancer Inst 103(3):250–263CrossRef
42.
Zurück zum Zitat Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D et al (2011) Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 117(16):3658–3669PubMedCrossRef Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D et al (2011) Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 117(16):3658–3669PubMedCrossRef
Metadaten
Titel
Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis
verfasst von
Mariaelena Pierobon
Cara L. Frankenfeld
Publikationsdatum
01.01.2013
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2013
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2339-3

Weitere Artikel der Ausgabe 1/2013

Breast Cancer Research and Treatment 1/2013 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.